List of Arena Pharmaceuticals patents

Patents where

Current Assignee

Name

Arena Pharmaceuticals

Name	Description	Patent Applicant	Current Assignee	Patent Jurisdiction	Patent Number	Date of Patent
‌ US Patent 10117851 Composition of a 5-HT2A serotonin receptor modulator useful for the treatment of disorders related thereto	Patent 10117851 was granted and assigned to Arena Pharmaceuticals on November, 2018 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	10117851	November 6, 2018
‌ US Patent 9567327 Imidazo[1,2-	Patent 9567327 was granted and assigned to Arena Pharmaceuticals on February, 2017 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	9567327	February 14, 2017
‌ US Patent 8415484 Substituted tricyclic acid derivatives as S1P1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders	Patent 8415484 was granted and assigned to Arena Pharmaceuticals on April, 2013 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	8415484	April 9, 2013
‌ US Patent 10301262 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(Compund1) for use in SIPI receptor-associated disorders	Patent 10301262 was granted and assigned to Arena Pharmaceuticals on May, 2019 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	10301262	May 28, 2019
‌ US Patent 11007175 Methods of treating conditions related to the S1P	Patent 11007175 was granted and assigned to Arena Pharmaceuticals on May, 2021 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	11007175	May 18, 2021
‌ US Patent 11478448 Compounds and methods for treatment of inflammatory bowel disease with extra-intestinal manifestations	Patent 11478448 was granted and assigned to Arena Pharmaceuticals on October, 2022 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	11478448	October 25, 2022
‌ US Patent 9085581 Processes for the preparation of S1P1 receptor modulators and crystalline forms thereof	Patent 9085581 was granted and assigned to Arena Pharmaceuticals on July, 2015 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	9085581	July 21, 2015
‌ US Patent 9522133 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders	Patent 9522133 was granted and assigned to Arena Pharmaceuticals on December, 2016 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	9522133	December 20, 2016
‌ US Patent 11091435 Crystalline L-arginine salt of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3, 4-tetrahydrocyclo-penta [b]indol-3-yl)acetic acid(compound1) for use in S1P	Patent 11091435 was granted and assigned to Arena Pharmaceuticals on August, 2021 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	11091435	August 17, 2021
‌ US Patent 7427487 Constitutively active CXCR3 G protein-coupled chemokine receptor and modulators thereof for the treatment of inflammatory disorders	Patent 7427487 was granted and assigned to Arena Pharmaceuticals on September, 2008 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	7427487	September 23, 2008
‌ US Patent 11149292 Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof	Patent 11149292 was granted and assigned to Arena Pharmaceuticals on October, 2021 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	11149292	October 19, 2021
‌ US Patent 9175320 Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof	Patent 9175320 was granted and assigned to Arena Pharmaceuticals on November, 2015 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	9175320	November 3, 2015
‌ US Patent 9126932 Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders	Patent 9126932 was granted and assigned to Arena Pharmaceuticals on September, 2015 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	9126932	September 8, 2015
‌ US Patent 9447041 Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof	Patent 9447041 was granted and assigned to Arena Pharmaceuticals on September, 2016 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	9447041	September 20, 2016
‌ US Patent 11426377 Method of treating conditions related to the PGI2 receptor		Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	11426377	August 30, 2022
‌ US Patent 8486646 Methods of using a G protein-coupled receptor to identify peptide YY (PYY) secretagogues	Patent 8486646 was granted and assigned to Arena Pharmaceuticals on July, 2013 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	8486646	July 16, 2013
‌ US Patent 8168624 Crystalline forms of (	Patent 8168624 was granted and assigned to Arena Pharmaceuticals on May, 2012 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	8168624	May 1, 2012
‌ US Patent 9597340 Cannabinoid receptor modulators	Patent 9597340 was granted and assigned to Arena Pharmaceuticals on March, 2017 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	9597340	March 21, 2017
‌ US Patent 11339172 Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of heart failure and disorders related thereto	Patent 11339172 was granted and assigned to Arena Pharmaceuticals on May, 2022 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	11339172	May 24, 2022
‌ US Patent 11771695 Cannabinoid receptor modulators	Patent 11771695 was granted and assigned to Arena Pharmaceuticals on October, 2023 by the United States Patent and Trademark Office.	Arena Pharmaceuticals	Arena Pharmaceuticals	United States Patent and Trademark Office	11771695	October 3, 2023
‌ US Patent 7368539 Non-endogenous, constitutively activated human serotonin receptors and small molecule modulators thereof	Patent 7368539 was granted and assigned to Arena Pharmaceuticals on May, 2008 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	7368539	May 6, 2008
‌ US Patent 7470699 Trisubstituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto	Patent 7470699 was granted and assigned to Arena Pharmaceuticals on December, 2008 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	7470699	December 30, 2008
‌ US Patent 7132426 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto	Patent 7132426 was granted and assigned to Arena Pharmaceuticals on November, 2006 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	7132426	November 7, 2006
‌ US Patent 7625906 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto	Patent 7625906 was granted and assigned to Arena Pharmaceuticals on December, 2009 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	7625906	December 1, 2009
‌ US Patent 8410119 Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto	Patent 8410119 was granted and assigned to Arena Pharmaceuticals on April, 2013 by the United States Patent and Trademark Office.		Arena Pharmaceuticals	United States Patent and Trademark Office	8410119	April 2, 2013

...

Results per page:

180 results

0 selected

180 results

0 selected